Evidence-based recommendations on acoramidis (Beyonttra) for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults. NICE has also produced technology appraisal ...

A 40-year-old woman with type 1 diabetes mellitus (T1DM) who injected insulin into her abdomen developed a firm subcutaneous mass in the right lower quadrant. Pathology after surgical excision showed ...

Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia The AL-ISS enables clinicians to ...

Almost four years after penning its first amyloidosis collaboration with Neurimmune, AstraZeneca has returned to pick up a second asset. The latest licensing deal involves NI009, a preclinical ...

Lectures on Tap series brings professors and other experts into Boston restaurants and bars for talks that mix big ideas with food and drink. Lectures on Tap, an event series, brings ticketed lectures ...

Please provide your email address to receive an email when new articles are posted on . A CRISPR-Cas9-based therapy reduced transthyretin levels in patients with hereditary amyloidosis and ...

Over time, transthyretin amyloidosis (ATTR) can damage the nerves, heart, and other organs. This may lead to complications like heart problems, nerve damage, and trouble with everyday bodily functions ...

The life expectancy for transthyretin (ATTR) amyloidosis varies from person to person. Your age, overall health, and primary symptoms all play a role. Transthyretin amyloidosis (ATTR) is a rare ...

A quiet revolution in care is helping patients with cardiac amyloidosis, a form of heart failure that long stumped doctors. By Simar Bajaj When James Hicks, 75, was diagnosed with heart failure, it ...

CTS is frequently associated with ATTRwt, a progressive disease that can lead to heart failure if untreated. Many patients with ATTRwt had a history of CTS, often diagnosed years before ATTRwt, ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. The Big ...